Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arndt Hartmann

Showing results (591-600 of 933) with videos related to

Pageof 94
Sort By:
Nature Communications|October 25, 2016
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancerSteffen Grampp, James L Platt, Victoria Lauer, et al.
Frontiers in Immunology|October 29, 2024
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevanceAnnalena Branz, Christian Matek, Fabienne Lange, et al.
Oncoimmunology|January 3, 2024
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancerLukas Heger, Gordon F Heidkamp, Lukas Amon, et al.
International Journal of Cancer|March 30, 2006
Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladderJohanna M M van Oers, Christoph Adam, Stefan Denzinger, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
BMC Cancer|December 15, 2012
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisNuran Bektas Serce, Andreas Boesl, Irina Klaman, et al.
Breast Cancer Research and Treatment|April 1, 2014
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristicsPeter A Fasching, Sebastian Weihbrecht, Lothar Haeberle, et al.
Oncoimmunology|January 18, 2026
NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cellsLukas Heger, Tomasz Kaszubowski, Lukas Amon, et al.
Archives of Gynecology and Obstetrics|September 8, 2012
Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsDavid L Wachter, Peter A Fasching, Lothar Haeberle, et al.
Pageof 94

Showing results (591-600 of 933) with videos related to

Sort By:
Pageof 94
Nature Communications|October 25, 2016
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancerSteffen Grampp, James L Platt, Victoria Lauer, et al.
Frontiers in Immunology|October 29, 2024
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevanceAnnalena Branz, Christian Matek, Fabienne Lange, et al.
Oncoimmunology|January 3, 2024
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancerLukas Heger, Gordon F Heidkamp, Lukas Amon, et al.
International Journal of Cancer|March 30, 2006
Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladderJohanna M M van Oers, Christoph Adam, Stefan Denzinger, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
BMC Cancer|December 15, 2012
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosisNuran Bektas Serce, Andreas Boesl, Irina Klaman, et al.
Breast Cancer Research and Treatment|April 1, 2014
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristicsPeter A Fasching, Sebastian Weihbrecht, Lothar Haeberle, et al.
Oncoimmunology|January 18, 2026
NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cellsLukas Heger, Tomasz Kaszubowski, Lukas Amon, et al.
Archives of Gynecology and Obstetrics|September 8, 2012
Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsDavid L Wachter, Peter A Fasching, Lothar Haeberle, et al.
Pageof 94